NOS2 and breast cancer: Importantly, the use of the iNOS inhibitor L-NIL restored NK cell ADCC activity (p < 0.01), indicating that NO suppresses NK cell function and that combined therapy with iNOS inhibitors may overcome trastuzumab resistance mediated by MDSCs, offering a promising approach for treating HER2-positive breast cancer.